Scientific Reports (Jul 2017)

Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto’s Thyroiditis

  • Qin Zhang,
  • Bo-Ji Liu,
  • Wei-Wei Ren,
  • Ya-Ping He,
  • Xiao-Long Li,
  • Chong-Ke Zhao,
  • Yi-Feng Zhang,
  • Wen-Wen Yue,
  • Jia-Yi Zheng,
  • Hui-Xiong Xu

DOI
https://doi.org/10.1038/s41598-017-05153-y
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 8

Abstract

Read online

Abstract To assess the association between BRAF V600E mutation and ultrasound (US) features in papillary thyroid carcinoma (PTC) patients with and without Hashimoto’s thyroiditis (HT). We retrospectively reviewed the US features and status of BRAF V600E mutation in 438 consecutive patients with surgically confirmed PTCs. The association between BRAF mutation and US features were analyzed. In addition, we conducted subgroup analyses in terms of coexistent HT. The BRAF mutation was found in 86.5% of patients (379 of 438). Patient age (OR: 1.028, P = 0.010), age ≥ 50 y (OR: 1.904, P = 0.030), and microcalcification (OR: 2.262, P = 0.015) on US were significantly associated with BRAF mutation in PTC patients. Solid component (OR: 5.739, P = 0.019) on US was the significant predictor for BRAF mutation in patients with HT, while age (OR: 1.036, P = 0.017) and microcalcification (OR: 3.093, P = 0.017) were significantly associated with BRAF mutation in patients without HT. In conclusion, older age and microcalcification are risk factors for BRAF mutation in PTC patients, especially in those without HT. For those with HT, however, PTCs with BRAF mutation tend to be solid on ultrasound. These factors might be considered when making treatment planning or prognosis evaluation.